- Home
- AIM vs MMA Comparison
AIM vs MMA Comparison
Compare AIM & MMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- MMA
- Stock Information
- Founded
- AIM 1966
- MMA 2013
- Country
- AIM United States
- MMA Australia
- Employees
- AIM N/A
- MMA N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- MMA
- Sector
- AIM Health Care
- MMA
- Exchange
- AIM Nasdaq
- MMA Nasdaq
- Market Cap
- AIM 9.8M
- MMA 9.0M
- IPO Year
- AIM N/A
- MMA 2024
- Fundamental
- Price
- AIM $0.14
- MMA $0.86
- Analyst Decision
- AIM Strong Buy
- MMA
- Analyst Count
- AIM 2
- MMA 0
- Target Price
- AIM $2.75
- MMA N/A
- AVG Volume (30 Days)
- AIM 1.5M
- MMA 77.4K
- Earning Date
- AIM 04-01-2025
- MMA 01-21-2025
- Dividend Yield
- AIM N/A
- MMA N/A
- EPS Growth
- AIM N/A
- MMA N/A
- EPS
- AIM N/A
- MMA N/A
- Revenue
- AIM $190,000.00
- MMA $375,175.00
- Revenue This Year
- AIM N/A
- MMA N/A
- Revenue Next Year
- AIM $1,693.10
- MMA N/A
- P/E Ratio
- AIM N/A
- MMA N/A
- Revenue Growth
- AIM N/A
- MMA 45.19
- 52 Week Low
- AIM $0.12
- MMA $0.75
- 52 Week High
- AIM $0.62
- MMA $5.25
- Technical
- Relative Strength Index (RSI)
- AIM 36.62
- MMA N/A
- Support Level
- AIM $0.12
- MMA N/A
- Resistance Level
- AIM $0.21
- MMA N/A
- Average True Range (ATR)
- AIM 0.02
- MMA 0.00
- MACD
- AIM -0.00
- MMA 0.00
- Stochastic Oscillator
- AIM 22.88
- MMA 0.00
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About MMA Alta Global Group Limited
Mixed Martial Arts Group Ltd formerly Alta Global Group Ltd is a technology company engaged in the provision and administration of mixed martial arts training programs, and gym programs. It provides subscription-based products and services, offering both B2B SaaS solutions and B2C products and programs, covering online engagement, online content, and immersive in-gym experiences. The company's business units are; Trainalta.com; Mixed Martial Arts.com; and Hype.Co, Mobile Marketing solution. Its Alta Platform serves as a comprehensive solution for martial arts and combat sports, offering a blend of four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community.